Results 211 to 220 of about 203,196 (295)

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Floaters as the First Manifestation of Chronic Myeloid Leukemia: A Case Report. [PDF]

Int J Mol Sci
Lee S, Kim J.
europepmc   +1 more source

FB23‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF/ERCC1 Complex

Cancer Science, EarlyView.
FB23‐2 potentiates cisplatin's antitumor efficacy in head and neck squamous cell carcinoma by disrupting XPF/ERCC1 complex assembly and nuclear translocation, thereby suppressing DNA damage repair machinery and amplifying platinum‐induced tumor cell death.
Yaoqi Jiang, Hongshi Cai, Yue Zhu, Jianfeng Liang, Hongyu Li, Fan Song, Ziyi Wang, Jinsong Hou   +7 more
wiley   +1 more source

Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective. [PDF]

Leukemia
Ernst P, Lohse C, Lauseker M, Geißler J, le Coutre P, Brümmendorf TH, Saußele S, Burchert A, Franke GN, La Rosée P, Brioli A, Schenk T, Fabisch C, Ernst T, Mehlkop G, Hochhaus A.   +15 more
europepmc   +1 more source

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

Cancer Science, EarlyView.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji, Narikazu Boku, Jun Adachi   +2 more
wiley   +1 more source

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation. [PDF]

Haematologica
Yuan M, Zhou L, Li W, Du X, Weng J, Yang L, Ma Y, Liu B, Liu Z, Wen Q, Zhao S, Zhang Y, Bai Q, Feng X, Han Y, Liu C, Meng L, Wang B, Ran X, Wang X, Zhang H, Zeng Y, Leng Q, Yu L, Li Z, Gale RP, Huang X, Jiang Q.   +27 more
europepmc   +1 more source

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

Cancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto, Mine Harada, Koichi Akashi, Toshihiro Miyamoto   +14 more
wiley   +1 more source

Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics. [PDF]

Front Pharmacol
Alqahtani S.
europepmc   +1 more source

Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms

Cancer Science, EarlyView.
In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley   +1 more source

Audiological profile for assessment of sensorineural hearing loss in treatment naïve chronic myeloid leukemia: impact of early TKI treatment on reversibility. [PDF]

Ann Hematol
Mamlekar H, Yadav S, Manogaran RS, Kashyap R, Rahman K, Gupta R, Chandra D, Singh M, Parmar A, Anand K.   +9 more
europepmc   +1 more source